€3.09
0.37% today
L&S, Jul 02, 10:28 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Share price

$3.33
-1.01 23.27% 1M
-0.88 20.90% 6M
-0.88 20.90% YTD
-7.44 69.08% 1Y
-64.52 95.09% 3Y
-52.57 94.04% 5Y
-52.57 94.04% 10Y
Nasdaq, Closing price Mon, Jul 01 2024
-0.07 2.06%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $746.94m
Enterprise Value $466.67m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.31
P/S ratio (TTM) P/S ratio 11.69
P/B ratio (TTM) P/B ratio 1.55
Sales growth (TTM) Sales growth 22.14%
Turnover (TTM) Turnover $63.88m
EBIT (operating result TTM) EBIT $-322.16m
Free cash flow (TTM) Free cash flow $-333.83m
Cash position $324.16m
EPS (TTM) EPS $-1.32
P/E ratio expected negative
P/S ratio expected 13.85
EV/Sales expected 8.66
Short interest 14.69%
Show more

Is CureVac N.V. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

CureVac N.V. Share analysis

Unlock Scores for Free

Analyst opinions

8 Analysts have issued a CureVac N.V. forecast:

4x Buy
50%
3x Hold
38%
1x Sell
13%

Analyst opinions

8 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from CureVac N.V.

Assets
Mar '24
408 408
Cash position 324 324
Claims 32 32
Inventories 28 28
Other current assets Other current assets Current assets 23 23
338 338
Property, plant and equipment 301 301
Financial assets - -
Intangible assets 34 34
Other fixed assets Other assets Fixed assets 2.37 2.37
Total assets 746 746
Liabilities
Mar '24
Equity 483 483
263 263
Current liabilities 181 181
Non-current liabilities 82 82
Total capital 746 746

Figures in millions USD.

Don't miss a thing! We will send you all news about the CureVac N.V. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

CureVac N.V. Share News

Neutral
Accesswire
8 days ago
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.
EQS
8 days ago
This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections o...
EQS
about one month ago
In der Phase-2-Studie werden die Reaktogenität, Sicherheit und Immunogenität verschiedener Dosisstufen eines modifizierten, multivalenten Impfstoffkandidaten untersucht, der für Antigene kodiert, die auf die drei von der WHO empfohlenen Grippestämme abgestimmt sind. Die Studie wird 250 gesunde jü...
More CureVac N.V. News

Company profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 1,172
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today